T CELL SUPPRESSORS OF ANTITUMOR IMMUNITY

The Production of Ly-1−,2+ Suppressors of Delayed Sensitivity Precedes the Production of Suppressors of Protective Immunity

BY ANTONIO DIGIACOMO AND ROBERT J. NORTH

From the Trudeau Institute, Inc., Saranac Lake, New York 12983

A central problem in tumor immunology has been to explain how immunogenic tumors escape destruction by the immune defenses of their immunocompetent hosts. The results of studies performed during the past few years in this laboratory (reviewed in 1) support the hypothesis that certain tumors with tumor-specific, transplantation antigens avoid destruction by the immune response of their hosts by evoking the production of a population of suppressor T cells that functions to downregulate the immune response before enough effector T cells are generated to cause tumor regression. These published studies (2, 3) show that growth of the immunogenic tumors under investigation evokes the generation of an underlying state of concomitant immunity, which develops progressively between days 6 and 9 of tumor growth, and which is mediated by Ly-2+ effector T cells. After day 9, however, there is progressive loss of effector T cells, and this is temporarily associated with the progressive acquisition of Ly-1+,2− suppressor T cells that are functionally defined by their ability to inhibit, on passive transfer, the expression of adoptive immunity against an established tumor in immunodepressed test recipients. It was postulated, on the basis of these and other results (1), that the loss of effector T cells results from negative regulation by tumor-induced suppressor T cells.

However, other investigators have described the generation of a different type of suppressor T cell in mice bearing progressive immunogenic tumors (reviewed in 4). This second type of suppressor T cell displays the Ly1−,2+, I-Jw membrane phenotype, is generated at a very early stage of tumor growth, and is defined by its ability to suppress, on passive transfer, a delayed-type hypersensitivity (DTH)1 reaction to tumor antigens in tumor-immune recipients. Because these suppressors of DTH are generated progressively during the first 6–7 d of tumor growth (5, 6), but are then progressively lost (6), it seems unlikely that they would exert a meaningful suppressor function in those situations where a tumor evokes the generation of a state of concomitant antitumor immunity that does not peak until day 9 of tumor growth, and does not undergo decay until after days 9–12.

The purpose of the study reported here, therefore, was to determine whether both types of suppressor T cells are generated in response to growth of a

1 Abbreviation used in this paper: DTH, delayed-type sensitivity.
chemically induced tumor that can evoke the generation of concomitant immunity. It will show that Ly-1−,2+ T cells that can suppress a tumor-specific DTH reaction, and Ly-1+,2− suppressor T cells that can suppress the expression of adoptive immunity, are generated in sequence in response to progressive growth of the immunogenic BALB/c Meth A fibrosarcoma. It will also show that the T cell suppressors that can suppress DTH fail to suppress the expression of adoptive immunity, and conversely, that T cells that suppress adoptive immunity fail to suppress DTH. It will be argued that because T cells that can suppress adoptive immunity are generated during the progressive decay of a concomitant immune response, it is they, rather than the earlier generated T cell suppressors of DTH, that serve best to explain the downregulation of concomitant immunity and failure of this form of immunity to cause tumor regression.

Materials and Methods

Mice. Specific pathogen-free CB6F1 (BALB/c × C57BL/6) and BALB/c female mice were supplied by the Trudeau Institute Animal Breeding Facility. The mice were free of viral pathogens, as evidenced by the results of routine serological screening performed by the Diagnostic Testing Service of Microbiological Associates, Bethesda, MD.

Tumor. The methylcholanthrene-induced Meth A fibrosarcoma syngeneic in BALB/c mice was used in this study. The tumor, grown as ascites in the peritoneal cavities of syngeneic hosts, was harvested in heparinized (5 U/ml) PBS, the cells were pooled, washed in PBS, resuspended in Fisher’s medium (Grand Island Biological Co., Grand Island, NY) containing 20% FCS and 10% DMSO, and were cryopreserved in small volumes over liquid nitrogen to serve as stock tumor. For each experiment a vial was thawed, the cells were washed in PBS and 2 × 10⁶ of them used to initiate peritoneal ascites tumors in semisyngeneic F1 hybrid mice. After 6 d of growth, the tumor cells were harvested in heparinized PBS, washed, and resuspended in PBS. In all experiments, tumors were initiated by injecting 10⁶ tumor cells in a volume of 50 μl of PBS.

Generation and Passive Transfer of DTH and Its Suppression. To induce a state of DTH, mice were immunized by intradermal injection of an admixture of 3 × 10⁶ Meth A cells and 50 μg of Propionibacterium acnes (formal in-killed Corynebacterium parvum from Burroughs Wellcome Co., Research Triangle Park, NC). This is known to result in a tumor that grows for 8–9 d then undergoes regression, leaving the animals immune to growth of a subsequent implant of tumor cells (7) and capable of mounting a DTH reaction to intrafootpad injection of Meth A cells (see later section). For passive transfer of DTH, the spleens of immunized mice were diced into small pieces, and the pieces were gently pushed through a 50-mesh stainless steel screen into PBS containing 1% FCS. The resulting cell suspension was triturated with a pasteur pipette to break up clumps, and passed through six layers of sterile surgical gauze to remove cell debris. The cells were washed twice in PBS, suspended in PBS containing 1% syngeneic mouse serum, and 1 ml of the cell suspension containing 1.5 spleen equivalents (about 1.5 × 10⁸ cells) was infused into appropriate recipients via a lateral vein.

Mice bearing a progressive Meth A tumor were used as donors of suppressor cells. Spleen cells were harvested from these mice at different times after initiating the tumor intradermally in the belly region with 10⁶ Meth A cells in 50 μl of PBS. To test for the presence of suppressor T cells, 1.5 organ equivalents (~1.5 × 10⁸) of spleen cells from tumor-bearing donors were infused into recipients that had been infused 1 h earlier with 1.5 organ equivalents (~1.5 × 10⁸) of sensitized spleen cells from immunized donors. An eliciting intrafootpad injection of 2 × 10⁶ mitomycin c–treated Meth A cells in 50 μl of PBS was then given, and DTH was monitored over the next 48 h by measuring increases in footpad thickness with dial calipers (Schnelltaster H.C. Droplin, Hessen, Federal Republic of Germany).

Passive Transfer of Immunity and Its Suppression. The assay for determining the
DiGIACOMO AND NORTH

presence of tumor-induced suppressor T cells that suppress protective immunity has been described elsewhere (2, 3). It involves showing that splenic T cells from tumor-bearing donors can, on passive transfer, inhibit the ability of passively transferred immune T cells to cause regression of a palpable 4-d tumor in T cell-deficient recipients. Briefly, donors of immune T cells were immunized by injecting them with an admixture of $3 \times 10^6$ living tumor cells and C. parvum as described for DTH above. T cell-deficient, tumor-bearing test recipients received one organ equivalent ($1.5-2.0 \times 10^8$) of immune spleen cells, followed 3 h later by one organ equivalent ($1.5-2.0 \times 10^8$) of suppressor spleen cells from mice bearing a progressive tumor. The test recipients were made T cell-deficient at 3 wk of age by thymectomy followed 1 wk later by lethal (950 rad) $\gamma$-irradiation. They were infused with $10^7$ syngeneic bone marrow cells immediately after irradiation, and used in experiments no sooner than 4 wk later.

Antibody Treatment. A hybridoma secreting anti-Ly-1.2 mAb (CP30) was a gift from Dr. Jan Klein, Max Planck Institute, Tubingen, Federal Republic of Germany. Anti-Ly-2.2 mAb was generated by a hybridoma (TIB-150) obtained from American Type Culture Collection (Rockville, MD). Anti-L3T4a mAb (8) produced by hybridoma GK-1.5 was obtained from Dr. M. J. Bevan, Scripps Clinic, La Jolla, CA. All hybridomas were grown to $5 \times 10^5$ cells/ml in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) containing 10% FCS and antibiotics. The cultures were centrifuged to pellet the cells and debris, and the supernatants were dispensed in small volumes and stored at $-20^\circ$C until needed. We used rabbit serum as a source of complement. It was obtained from rabbits bred at the Trudeau Institute and selected on the basis of minimal cytotoxicity of their sera for mouse thymocytes. For deletion of T cell subsets, spleen cells were incubated at $2 \times 10^7$/ml in a 1:5 dilution of the appropriate antibody supernatant at 4°C for 45 min, and then in a 1:10 dilution of rabbit serum at 37°C for 60 min, as described elsewhere (2, 3).

Cyclophosphamide Treatment. Cytoxan was obtained from Mead Johnson & Co. (Evansville, IN) and dissolved in sterile saline (15 mg/ml). Freshly prepared solutions were injected intravenously into tumor-bearing suppressor donors 24 h before their lymphoid cells were harvested for passive transfer.

Results

Generation of DTH to Tumor Antigens and Its Passive Transfer. To test tumor-bearers for cells that suppress DTH, it was first necessary to show that true DTH is generated in response to the Meth A tumor. This required showing that a Meth A-immunized host can mount an inflammatory reaction to an injection of Meth A cells and that the reaction has delayed kinetics. It also required showing that the ability to mount the reaction can be passively transferred to recipients with Ly-1+,2-, L3T4a+ T cells.

It can be seen in Fig. 1 that when mice were injected intradermally with an admixture of $3 \times 10^6$ living Meth A cells and C. parvum, they developed a palpable tumor which grew for 8–9 d and then underwent complete regression. It can also be seen that when these mice were challenged in a hind footpad with an eliciting dose of $2 \times 10^6$ mitomycin c-treated Meth A cells, they had an 18-h inflammatory reaction, the size of which depended on the time of tumor growth or regression that the eliciting injection of tumor cells was given. The ability to mount an inflammatory reaction was acquired by day 3 of immunization, peaked on day 8, and then progressively decayed until about day 20 when the mice were left with a relatively low, but stable state of sensitivity that lasted beyond 30 d of immunization.

Fig. 2 shows that the intrafootpad inflammatory reaction described above had the kinetics of a DTH reaction. It can be seen that when mice were given an
FIGURE 1. Immunization for DTH by intradermal injection of an admixture of \(3 \times 10^6\) tumor cells and 100 \(\mu\)g of C. parvum resulted in 8–9 d of growth of the immunizing tumor that emerged, followed by complete tumor regression (top). The ability to mount an 18-h DTH reaction to an intrafootpad injection of \(2 \times 10^6\) mitomycin c-treated tumor cells (bottom) was acquired progressively during the first 8 d of immunization, peaked immediately before a tumor regression, and then progressively decayed to a stable level from day 21 on. Means and SEM of five mice are shown.

FIGURE 2. Time course of development of the expression of a DTH reaction to an intrafootpad injection of \(2 \times 10^6\) mitomycin c–treated tumor cells given on day 8 (peak) of immunization, as shown in Fig. 1. It is obvious that the reaction had delayed kinetics. Means and SEM of five mice are shown.
FIGURE 3. The ability of immunized mice to express a DTH reaction could be passively transferred to normal recipients with donor lymphoid cells. The lymphocytes that transferred immunity were Ly-1⁻,2⁻, L3T4⁺ T cells, in that they were destroyed by treatment with anti-Ly-1 antibody, or anti-L3T4 antibody and complement, but not by anti-Ly-2 antibody and complement. In this experiment donor spleen cells were harvested on day 8 of immunization, and the recipients received the eliciting dose of mitomycin c-treated tumor cells 1 h after receiving donor cells. Means and SEM of five mice per group are shown.

Intrafootpad injection of mitomycin c–treated tumor cells on day 8 of immunization there was minimal footpad swelling at 3 h, maximum swelling at 18 h, and then a progressive decrease in footpad thickness. Additional evidence that the reaction was true DTH is shown in Fig. 3, where it can be seen that the ability to mount the reaction could be passively transferred from immunized mice to normal recipient mice with spleen cells. Fig. 3 also shows that the responsible cells were of the Ly-1⁻,2⁻, L3T4⁺ helper phenotype, in that their ability to transfer DTH was eliminated by treatment with either anti-Ly-1.2 antibody and complement, or anti-L3T4a antibody and complement, but not by treatment with anti-Ly-2.2 antibody and complement.

Spleen Cells from Mice Bearing a 6-d Tumor, But Not a 16-d Tumor, Suppress Expression of Passively Transferred DTH. According to the results of others, lymphoid cells obtained from mice bearing the syngeneic S1509a sarcoma (4, 5) or Meth A fibrosarcoma (6) can, upon passive transfer, suppress DTH reactions to these tumors in appropriately immunized recipients. To determine whether similar suppressor cells are generated in response to the Meth A tumor under study in this laboratory, an attempt was made to suppress passively transferred Meth A–specific DTH with spleen cells from donors bearing a progressive Meth A tumor. This involved infusing spleen cells from suppressor donors bearing either a 6-d, or 16-d, progressive Meth A tumor into recipients that had received spleen cells from immunized donors 1 h earlier. The recipients were then challenged in a hind footpad with mitomycin c–treated Meth A cells. The sensitized T cells for transferring DTH were harvested from donors with peak DTH on day 8 of immunization with the C. parvum–tumor cell admixture, as shown in Fig. 1.

It can be seen in Fig. 4 that spleen cells from mice bearing a 6-d Meth A tumor could, on passive transfer, suppress the expression of passively transferred DTH
T CELL SUPPRESSORS OF ANTITUMOR IMMUNITY

FIGURE 4. The expression of passively transferred DTH was suppressed by passive transfer of spleen cells from donor mice bearing a day 6 (5 mm diameter) tumor, but not from donors bearing a day 16 (12 mm diameter) tumor. Suppressor cells were transferred 1 h after transferring sensitized T cells, and 2 h after challenging the recipients with antigen. Means and SEM of five mice per group are shown. Asterisk indicates p < 0.05. Supp, suppressor cells.

Membrane Phenotype and Cyclophosphamide Sensitivity of Suppressors of DTH.

Fig. 6 shows that when cells from 6-d tumor-bearing donors were treated with anti-Ly-2.2 antibody and complement, their ability, on passive transfer, to suppress a DTH reaction in recipients of sensitized T cells was completely abolished. In contrast, treatment with anti-Ly-1.2 mAb and complement had no effect on the ability of the cells to suppress DTH. Thus, in keeping with the findings of others (4–6), spleen cells from a 6-d tumor bearer that suppress the expression of passively transferred DTH bear the Ly1−,2+ membrane phenotype.

These suppressors also proved highly sensitive to cyclophosphamide, in that a single dose of 20 or 100 mg/kg given intravenously to mice bearing a 6-d Meth A tumor caused complete elimination of T cells that could, upon passive transfer, suppress the expression of passively transferred DTH (Fig. 7).

Kinetics of Generation of T Cells that Suppress DTH and T Cells that Suppress Adoptive Immunity. By using the assay for suppression of DTH described above, it was possible to follow the kinetics of generation of T cells that suppress DTH against time of tumor growth. Fig. 8 shows that cells that can, upon passive transfer, suppress the expression of passively transferred DTH were first detected
FIGURE 5. Kinetics of development of an intrafootpad DTH reaction in adoptively immunized recipients, and in adoptively immunized recipients that received spleen cells from donors bearing a day 6 or day 16 tumor. Suppressor cells from donors with a day 6 tumor blocked the DTH reaction at any early stage of its development. In contrast, spleen cells from donors with a day 16 tumor had no suppressive effect. Means of five mice per group are shown. Cells transferred: (O) immune, (A) immune + 6-d suppression, (■) immune + 16-d suppression.

FIGURE 6. Time course of generation of DTH suppressors in the spleen during tumor growth. Cells that could suppress a DTH reaction in adoptively immunized recipients upon passive transfer were generated progressively during the first 6 d of tumor growth, and were then progressively lost. Means of five mice per group are shown.

in the spleens of tumor-bearing donors around day 3 of tumor growth, reached maximum production on about day 6, and declined progressively in number thereafter.

In contrast, the generation of suppressor T cells that could suppress adoptive immunity against an established tumor in T cell–deficient recipients occurred much later. Fig. 9 serves to confirm results previously published (2, 3) by showing that spleen cells that can, upon intravenous infusion, inhibit the ability of
intravenously infused immune T cells to cause regression of an established tumor in T cell-deficient recipients were not acquired progressively in the spleens of tumor bearers until after 9–12 d of tumor growth. Therefore, at a time when the host possesses maximal numbers of T cells that can suppress DTH (Fig. 8), it does not possess T cells that can suppress the expression of adoptive immunity in a T cell-deficient recipient.

**T Cells that Suppress DTH Do Not Suppress Immunity in the Same Recipients.** It was shown above that T cells from day-6 Meth A bearers can convincingly suppress, on passive transfer, the expression of passively transferred DTH, but not the expression of passively transferred immunity against an established tumor in T cell-deficient recipients. This indicated the distinct possibility that suppression of DTH is not the same as suppression of protective immunity. Therefore, it was important to determine, with the Meth A tumor under study in this
Discussion

Two models of T cell-mediated suppression of antitumor immunity have been studied in some detail. One is based on the capacity of T cells from tumor-
**Figure 10.** Evidence that suppression of DTH did not result in suppression of immunity. Passive transfer of suppressor cells from donors with a day 6 tumor failed to suppress the ability of immunized mice to express immunity against an intrafootpad implant of $2 \times 10^6$ living tumor cells, even though the 18-h DTH reaction to the living implant was severely suppressed. The 18-h increase in footpad thickness that resulted from implanting living tumor cells was identical to the increase in footpad thickness that resulted from implanting the same number of mitomycin c-treated tumor cells (DTH CONTROL). Regardless of whether or not they received T cell suppressors of DTH, the immunized recipients could cause complete regression of the tumor that emerged from the implant. In contrast, the tumor implant grew progressively in normal mice. Means of five mice per group are shown. Supp. suppressor cells.

bearing donors to suppress, upon passive transfer, the expression of a tumor-specific DTH reaction to an injection of tumor cells in tumor-immunized recipients. The other is based on the capacity of T cells from tumor bearers to suppress, upon passive transfer, the expression of adoptive immunity against an established tumor in T cell–deficient recipients. The tumor on which the first mentioned model is based is the S1509a sarcoma syngeneic in A/J mice (reviewed in 4), although similar results have been published more recently with the BALB/c Meth A fibrosarcoma (6, 9). According to studies with these two tumors, T cells that can suppress a tumor-specific DTH reaction in immunized recipients are produced very early (24-48 h) after implanting tumor cells subcutaneously, increase in number to peak around days 6–7 of tumor growth, and are then progressively lost as the tumor grows larger in size. These suppressors display the Ly-1*,2*, I-J+ membrane phenotype and are functionally eliminated by giving the host as little as 20 mg/kg of cyclophosphamide.

The second major model of tumor-induced suppression is based on the ability of T cells from tumor-bearing donors to inhibit, on passive transfer, the expression of passively transferred immunity against a relatively large palpable tumor in T cell–deficient recipient mice. This model of suppression of immunity developed from the initial finding in this laboratory (10) that tumor-sensitized T cells from immunized donor mice failed, on passive transfer, to cause regression of a recipient tumor, unless the recipient had been made T cell–deficient by
thymectomy and irradiation. It was reasoned that sensitized T cells express their
function in T cell-deficient recipients, but not in immunocompetent recipients,
because the latter recipients acquired suppressor T cells in response to progressive
growth of their tumor. Evidence consistent with this interpretation was
supplied by the demonstration that the obstacle to adoptive immunotherapy
could be passively transferred. In other words, it was shown (10, 11) that an
infusion of T cells from tumor-bearing donors, but not from normal donors,
could suppress the ability of T cells from immunized donors to cause regression
of a palpable tumor in T cell-deficient recipients. It was shown later (12) that
the suppressor T cells detected by this assay are specific for the tumor that evokes
their generation. Moreover, they are different in a number of ways from the
suppressor T cells that function to suppress tumor-specific DTH. For example,
unlike the suppressor of DTH, the suppressors of adoptive immunotherapy bear
the Ly-1+,2- membrane phenotype, and are not generated until late in tumor
growth, when the tumor grows beyond about 8 mm in diameter (2, 3). More
recent studies show (A. DiGiacomo and R. J. North, manuscript submitted for
publication) that these suppressor T cells also display the L3T4 antigen. Again,
the suppressors of adoptive immunotherapy used against an established tumor
are not as sensitive to cyclophosphamide as the suppressors of DTH. Whereas,
as shown here and elsewhere (9), suppressors of Meth A-specific DTH are
destroyed by a 20 mg/kg dose of the drug, it requires a 100 mg/kg dose to
destroy the suppressors of adoptive immunity (13).

However, in spite of the differences between these two types of suppressor T
cells, this study leaves no doubt that both types are produced in response to the
Meth A fibrosarcoma under study in this laboratory. The results show that Ly-
1+,2+ suppressor T cells defined by their ability to suppress DTH are generated
progressively during the first 6 d of tumor growth, whereas suppressor T cells
that can suppress the expression of adoptive immunity are generated later in
tumor growth when the production of the suppressors of DTH is on the wane.
There is a need, therefore, to discuss the functional significance of each type of
suppressor T cell, with a view to deciding how each type might explain downreg-
ulation of the antitumor immune response.

In this regard, it can be stated first, that because the reason for postulating
the existence of suppressor T cells in tumor-bearing mice is to explain how
tumors avoid being destroyed by an antitumor immune response, suppressor
cells that can suppress a proven antitumor effector mechanism in vivo are likely
to be more important than those that suppress the expression of a correlate of
immunity, like DTH. It should be mentioned, however, that the T cell suppress-
ors of DTH induced by the S1509a sarcoma were originally defined in terms
of their ability to partly suppress the expression of immunity to growth of a
tumor implant in immunized recipients (14). More recently published findings
(6) with the Meth A fibrosarcoma indicate, nevertheless, that suppression of a
DTH reaction to this tumor by passively transferred Ly-1+,2+ suppressors may
not necessarily be associated with suppression of immunity. The results presented
here serve to show that this is the case. They reveal that, although T cell
suppressors of DTH can efficiently suppress a DTH reaction to an implant of
living tumor cells in immunized recipients, they fail to suppress, to any extent,
the expression of immunity to growth of the same implant. At this stage of the investigation, therefore, it is difficult to see a role for the T cell suppressors of tumor-specific DTH in the escape of the immunogenic Meth A fibrosarcoma from immunity.

Even so, the fact that suppressor T cells that can suppress tumor-specific DTH reaction in immunized recipients are generated in response to tumor growth, means that these suppressors must play some part in the antitumor immune response. There can be little doubt that the sensitivity reaction that these suppressors suppress is true DTH, because it was shown here that it develops with delayed kinetics and is mediated by Ly-1+,2-, L3T4a+ T cells. However, it needs to be appreciated that the DTH described here and elsewhere (4–6, 9) was induced by immunization, rather than by progressive tumor growth. To understand the meaning of suppression of DTH, we need to first determine whether tumor-specific DTH represents a mechanism of tumor rejection, and second, whether it can develop in a tumor-bearing animal in the absence of suppressors of DTH. Presumably such evidence will be forthcoming. In the meantime, an explanation of tumor escape based on suppression of concomitant immunity by Ly-1+,2- suppressor T cells seems relatively easy to accept, because these suppressors have the capacity to suppress a mechanism of immunity that can cause the regression of a relatively large tumor mass. They have the same surface phenotype (2, 3) as the T cells that can passively transfer immunosuppression in other in vivo models of antitumor immunity (13, 14), and that can passively transfer tolerance to allografts in rats (15). The possibility that these suppressor T cells are “inducer suppressors,” that recruit Ly-1-,2+ “effector suppressors” that ultimately express suppression is worth considering, but has been questioned (1, 17). In any case, it would not explain why suppression of DTH by Ly-1-,2+ suppressor T cells is not associated with suppression of immunity.

Summary

The results of this study show that during growth of the immunogenic Meth A fibrosarcoma, two different types of suppressor T lymphocytes are generated in sequence. One type is generated during early tumor growth, reaches peak number around day 6, and is progressively lost thereafter. It is defined by its ability, upon passive transfer, to suppress the expression of a DTH reaction to tumor antigens in tumor-immunized recipients. It bears the Ly1-,2+ membrane phenotype and is sensitive to relatively low doses of cyclophosphamide. In contrast, the second type of suppressor cell is not detected until after day 9 of tumor growth, and is defined by its ability to inhibit, upon passive transfer, the expression of adoptive immunity against an established tumor in T cell–deficient recipients. According to previous studies it bears the Ly1+,2−, L3T4a+ membrane phenotype and is less sensitive to cyclophosphamide than the T cell suppressor of DTH. It is argued that this second type of suppressor T cell seems likely to be responsible for the escape of immunogenic tumors from antitumor immunity, because it can suppress the expression of a powerful mechanism of antitumor immunity in recipient mice, and is generated progressively as the tumor-bearing host loses concomitant immunity. In contrast, although the Ly-1−,2+ T cell
suppressors of DTH can efficiently suppress a DTH reaction to an implant of living tumor cells, they fail to suppress the expression of immunity to the same implant.

Received for publication 29 May 1986 and in revised form 26 June 1986.

References

1. North, R. J. 1985. Down-regulation of antitumor immunity. Adv. Cancer Res. 45:1.
2. North, R. J., and I. Bursuker. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1"2" suppressor T cells down-regulate the generation of Ly-1"2" effector T cells. J. Exp. Med. 159:1295.
3. North, R. J., and E. S. Dye. 1985. Ly1"2" suppressor T cells down-regulate the generation of Ly1"2" effector T cells during progressive growth of the P815 mastocytoma. Immunology. 54:47.
4. Greene, M. I. 1980. The genetic and cellular basis of regulation of the immune response to tumor antigens. Contemp. Top. Immunobiol. 11:81.
5. Fujimoto, S., M. I. Greene, and A. H. Sehon. 1975. Immunosuppressor T cells in tumor bearing hosts. Immunol. Commun. 4:207.
6. Hawrylko, E. 1982. Tumor bearer T cells suppress BCG-potentiated antitumor responses. I. Requirements for their effect. Cell. Immunol. 66:121.
7. Dye, E. S., R. J. North, and C. D. Mills. 1981. Mechanisms of antitumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J. Exp. Med. 154:609.
8. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, and F. W. Fitch. 1984. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J. Immunol. 131:2445.
9. Hawrylko, E., C. A. Mele, and O. Stutman. 1982. Tumor bearer T cells suppress BCG-potentiated antitumor response. II. Characteristics of the efferent phase suppressor. Cell. Immunol. 66:139.
10. Berendt, M. J., and R. J. North. 1980. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151:69.
11. Dye, E. S., and R. J. North. 1981. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J. Exp. Med. 154:1033.
12. Dye, E. S., and R. J. North. 1984. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J. Leuk. Biol. 36:27.
13. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155:1063.
14. Fujimoto, S., M. I. Greene, and A. H. Sehon. 1976. Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J. Immunol. 116:791.
15. Ulrich, S. E., and M. L. Kriple. 1984. Mechanisms in the suppression of tumor rejection produced in mice by repeated UV irradiation. J. Immunol. 133:2786.
16. Mullen, C. A., J. L. Urban, C. Van Waes, D. A. Rowley, and H. Schreiber. 1985. Multiple cancers: tumor burden permits the outgrowth of other cancers. J. Exp. Med. 162:1665.
17. Hall, B. M., M. E. Jelbant, K. E. Gurley, and S. E. Dorsch. 1985. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine: mediation of specific suppression by T helper/inducer cells. *J. Exp. Med.* 162:1683.